Myonex ApS: Financial statements 2024
CVR: 39905094
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Myonex ApS (CVR 39905094) has filed annual accounts for 2024. In 2024, the company reported a gross profit of EUR 2,591,932 and a net result of EUR 2,155,499 compared with EUR 1,909,497 the year before. That is a decrease of 2.3% compared with the year before. Equity in the 2024 report amounted to EUR 18,936,003. The solvency ratio was 98.1%.
- Gross Profit
- EUR 2,591,932
- Profit/Loss
- EUR 2,155,499
- Equity
- EUR 18,936,003
- Total Assets
- EUR 19,307,026
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 2.6M EUR | 2.2M EUR | 18.9M EUR | - |
| 2023 | - | 2.7M EUR | 1.9M EUR | 16.8M EUR | - |
| 2022 | - | 11.4M EUR | 8.8M EUR | 14.9M EUR | - |
| 2021 | - | 8.1B EUR | 6.2B EUR | 6.1B EUR | - |
| 2020 | - | -104K EUR | -105K EUR | -179K EUR | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Myonex ApS has published its annual report for 2023. Gross profit came to DKK 2,653,832, and the net result was DKK 1,909,497.
About Myonex ApS
Myonex ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Myoderm ApS. The management consists of Gregory Thomas Lavin and Michael Allen Cohen. The company is owned by Myonex, LLC. In 2025, the company reported a gross profit of EUR 1,009,020 and a net result of EUR 580,466 compared with EUR 2,155,499 the year before. Equity in the 2025 report amounted to EUR 19,516,469.